Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920594 | 1.00 | CA1 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12920589 | 1.00 | CA1 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12920692 | 0.86 | ALOX5AP (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2251856 | 0.86 | ALOX5AP (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2247662 | 0.85 | ALOX5AP (0.45) | CA1CA2CA12CA7CA9 | |
| Terephthalic Acid SCHEMBL9341496 | 0.84 | ALOX5AP (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL259032 | 0.83 | ALOX5AP (0.63) | ALOX5APHSD11B1 | |
| SCHEMBL12954721 | 0.83 | ALOX5AP (0.63) | ALOX5APHSD11B1 | |
| SCHEMBL9341488 | 0.83 | ALOX5AP (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12920595 | 0.81 | ALOX5AP (0.57) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989472-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2209761-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | disclosed |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2007111864-A2 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | PTGIS, PTGS1, LTC4S | CA1 2901/4885CA2 2371/4885CA12 4338/4885 |
| US-20090209564-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use | GCGR, GLP1R, GPR119 | CA1 2428/4885CA2 1288/4885CA12 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.